Interim Results

AI SummaryClose X

Cizzle Biotechnology Holdings PLC announced its interim results for the six months ended 30 June 2025. The company received US$400,000 of the agreed US$2.4 million up-front fees and advanced royalty payments, with a further US$125,000 received in July, totaling US$525,000. A convertible loan note raised £150,000 to support growth and partnerships for its CIZ1B early cancer test. The company reported a loss for the period of £368,000, a significant decrease from the £1,411,000 loss in the first half of 2024. Cash balances stood at £182,000 as of 30 June 2025. The loss per share was 0.09p, compared to a loss of 0.37p in the prior year period.

Disclaimer*

UK 100

Latest directors dealings